Novo Nordisk Shares - Search News

Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling another 2.6% through 10:10 a.m. ET on Thursday.

Seeking Alpha · 1d

Novo Nordisk: Dips Like These Come Once Every Few Years

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy with promising growth in obesity care.

YAHOO!Finance · 11d

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.

Wall Street Journal · 9d

Novo Nordisk Earnings Boost Stock in Ozempic Maker

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig

Investing.com on MSN · 2d

Bernstein raises Novo Nordisk stock target to DKK620

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating. The $365 billion market cap company,

3hon MSN

Novo Nordisk stock is having a rough week after that Hims & Hers Super Bowl ad

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

11hon MSN

Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

12h

How Is The Market Feeling About Novo Nordisk?

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

10d

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

22h

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...

manilatimes7d

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have ...

8don MSN

Novo Nordisk Outlook Provides Some Welcome Relief

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

9don MSN

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results